

## **Position on Value and Pricing of Medicines**

### **Background**

Astellas contributes to improving the health of people around the world by providing innovative medicines to patients. We do this by investing in leading-edge research and development for innovative medicines and by supporting patients to the access to the medicines they need.

Astellas engages with many stakeholders in the healthcare community to find ways to meet the dual imperatives of working towards affordable access for patients while maintaining proper incentives for companies required to sustain the promise of future innovative medicines.

### **Our Position**

Astellas believes that the price of medicines should be a fair reflection of the value they bring to patients, healthcare systems, and society as a whole. Improved patient outcomes in mortality, morbidity and quality of life are our first and foremost priorities. However, we also believe that when determining the value of medicines, stakeholders must take into consideration: the novelty of the science; the strength and quality of the evidence; the clinical benefits relative to existing treatments; the economic benefits for both patients and healthcare systems; and the ability of healthcare systems to provide broad access to patients. Throughout the research and development process, we engage with a range of relevant stakeholders, including healthcare providers, payers and patients, to gain diverse perspectives on these and other factors.

Astellas understands affordability of medicines is one factor that can impact patients' access to medicines. We work with a broad array of healthcare stakeholders to develop sustainable solutions to address issues of affordability. As part of this, we explore various pricing and access solutions, such as patient access initiatives and value-based approaches to the pricing of our medicines, both of which take into consideration a variety of factors, including geographic and socio-economic circumstances.

Astellas is committed to working with stakeholders to find durable solutions that enable patients to have affordable access to our medicines, while still enabling us to invest in innovative new medicines.